Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | SCD | O00767 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ME2 | P23368 | 2/20 | 0.49 |
| ▸ | ME1 | P48163 | 2/20 | 0.49 |
| ▸ | ME3 | Q16798 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673627 | 0.94 | SMN1; SMN2 (0.56) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL3672179 | 0.90 | NPC1 (0.51) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL3672965 | 0.87 | LMNA (0.55) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL3667718 | 0.87 | SCD (0.61) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL3669106 | 0.87 | SCD (0.49) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL3668233 | 0.86 | RAB9A (0.55) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL3672660 | 0.86 | RAB9A (0.67) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL3668913 | 0.86 | FOLH1 (0.49) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL3671024 | 0.85 | SCD (0.47) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL3680606 | 0.85 | FOLH1 (0.48) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763350-B1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-12-21 | — | — | EP | claimed |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-08-06 | — | — | US | claimed |
| CN-1997371-A | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2007-07-11 | — | — | CN | claimed |
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-06-02 | — | — | US | claimed |
| EP-1763350-B1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-12-21 | — | — | EP | disclosed |
| EP-2266566-A2 | Nicotinamide derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2010-12-29 | — | — | EP | disclosed |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-08-06 | — | — | US | disclosed |
| CN-1997371-A | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2007-07-11 | — | — | CN | disclosed |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-19 | — | — | US | disclosed |
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | NAMPT, NNT, NNMT | RAB9A 1717/4885SMN1; SMN2 112/4885NPC1 94/4885 |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | APP, BACE1, PSEN1 | RAB9A 1976/4885SMN1; SMN2 123/4885NPC1 31/4885 |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | NAMPT, NNT, NNMT | RAB9A 1717/4885SMN1; SMN2 112/4885NPC1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.